Guangxin Xia

Dr. Guangxin Xia

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CSChen Shi
Chen Shi
QWQian Wang
Qian Wang
XLXuemei Liao
Xuemei Liao
HGHui Ge
Hui Ge
GHGuoyong Huo
Guoyong Huo
YLYanjun Liu
Yanjun Liu

1 May 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CSChen Shi
Chen Shi
QWQian Wang
Qian Wang
XLXuemei Liao
Xuemei Liao
HGHui Ge
Hui Ge
GHGuoyong Huo
Guoyong Huo
GXGuangxin Xia
Guangxin Xia

26 February 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
XLXuemei Liao
Xuemei Liao
YHYuan Hong
Yuan Hong
YMYu Mao
Yu Mao
NCNa Chen
Na Chen
QWQian Wang
Qian Wang
YLYanJun Liu
YanJun Liu
The cyclin‐dependent kinase (CDK)4/6‐cyclin D1‐Rb‐p16/ink4a pathway is responsible for regulating cell progression past the G1 restriction point during the cell cycle. The development of a majority of human tumors is associated with dysregulation of this pathway, resulting in increased cancer cell proliferation. Both CDK4 and CDK6, well‐validated cancer drug targets, function primarily as catalytic enzymes that mediate the phosphorylation of retinoblastoma protein (Rb). Here, we determined that SPH3643 is a novel potent antiproliferative agent that inhibits CDK4/6 kinase activity. In biochemical assays, SPH3643 showed more potent inhibition of both CDK4 and CDK6 than did 2 published CDK4/6 inhibitors, LY2835219 and palbociclib, and had better selectivity than LY2835219. Further in vitro study revealed that SPH3643 blocked Cdk/Rb signaling by inhibiting the phosphorylation of RbSer780 and arrested the MCF‐7 cancer cells at G0/G1 phase, resulting in marked inhibition of the proliferation of Rb‐positive cancer cell lines. In vivo SPH3643 treatment in mice bearing xenograft tumor models of breast cancer, colon cancer, acute myelocytic leukemia, and glioblastoma resulted in significant decreases in tumor growth. SPH3643 was able to particularly strongly inhibit glioblastoma (U87‐MG) cell growth in the brains of orthotopic carcinoma xenograft mice due to its high degree of intracerebral penetration and significant persistence in this setting. Together these results revealed that SPH3643 is a potent, orally active small‐molecule inhibitor of CDK4/6 with robust anticancer efficacy and a high degree of blood‐brain barrier permeability.


7 August 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
JXJinbao Xiang
Jinbao Xiang
YWYuji Wang
Yuji Wang
WWWanhe Wang
Wanhe Wang
JYJianxin Yu
Jianxin Yu
LZLianyou Zheng
Lianyou Zheng
XBXu Bai
Xu Bai

7 September 2019 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
LZLeduo Zhang
Leduo Zhang
YMYu Mao
Yu Mao
ZGzhiwei gao
zhiwei gao
XCXiao-yan Chen
Xiao-yan Chen
Xin LiXin Li
Xin Li
GXGuangxin Xia
Guangxin Xia